Search research articles
Contact Us
Filters
Showing results (31-40 of 94) with videos related to
Page
of 10
Sort By:
Journal of Cardiovascular Pharmacology
|
June 17, 2009
Evolving mechanisms of action of beta blockers: focus on nebivolol
R Preston Mason, Thomas D Giles, James R Sowers
Atherosclerosis
|
August 9, 2015
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
Kenneth M Borow, John R Nelson, R Preston Mason
Circulation
|
June 3, 2004
Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress
R Preston Mason, Mary F Walter, Robert F Jacob
Biochimica Et Biophysica Acta. Biomembranes
|
March 6, 2020
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Samuel C R Sherratt, Rebecca A Juliano, R Preston Mason
Journal of Cardiovascular Pharmacology
|
March 6, 2016
Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents
R Preston Mason, Samuel C R Sherratt, Robert F Jacob
Current Diabetes Reports
|
October 23, 2020
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Xiaowen Wang, Subodh Verma, R Preston Mason, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism
|
June 23, 2022
Omega-3-fatty acids: Do they prevent cardiovascular disease?
R Preston Mason, Samuel C R Sherratt, Robert H Eckel
Biochimica Et Biophysica Acta. Biomembranes
|
December 25, 2018
Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length
Samuel C R Sherratt, Pierre Villeneuve, Erwann Durand, et al.
Postgraduate Medicine
|
October 5, 2017
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
John R Nelson, Wayne S True, Viet Le, et al.
European Journal of Preventive Cardiology
|
January 3, 2024
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur, R Preston Mason, Ph Gabriel Steg, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 94) with videos related to
Sort By:
Page
of 10
Journal of Cardiovascular Pharmacology
|
June 17, 2009
Evolving mechanisms of action of beta blockers: focus on nebivolol
R Preston Mason, Thomas D Giles, James R Sowers
Atherosclerosis
|
August 9, 2015
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
Kenneth M Borow, John R Nelson, R Preston Mason
Circulation
|
June 3, 2004
Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress
R Preston Mason, Mary F Walter, Robert F Jacob
Biochimica Et Biophysica Acta. Biomembranes
|
March 6, 2020
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Samuel C R Sherratt, Rebecca A Juliano, R Preston Mason
Journal of Cardiovascular Pharmacology
|
March 6, 2016
Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents
R Preston Mason, Samuel C R Sherratt, Robert F Jacob
Current Diabetes Reports
|
October 23, 2020
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Xiaowen Wang, Subodh Verma, R Preston Mason, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism
|
June 23, 2022
Omega-3-fatty acids: Do they prevent cardiovascular disease?
R Preston Mason, Samuel C R Sherratt, Robert H Eckel
Biochimica Et Biophysica Acta. Biomembranes
|
December 25, 2018
Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length
Samuel C R Sherratt, Pierre Villeneuve, Erwann Durand, et al.
Postgraduate Medicine
|
October 5, 2017
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
John R Nelson, Wayne S True, Viet Le, et al.
European Journal of Preventive Cardiology
|
January 3, 2024
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur, R Preston Mason, Ph Gabriel Steg, et al.
Page
of 10